Lymphocytic Infiltration and Immune Activation in Metallothionein Promoter–Exendin-4 (MT-Exendin) Transgenic Mice
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) exhibits considerable potential for the treatment of type 2 diabetes because of its effects on stimulation of insulin secretion and the inhibition of gastric emptying, appetite, and glucagon secretion. However, native GLP-1 undergoes rapid enzymatic inactivation, prompting development of long-acting degradation-resistant GLP-1 receptor agonists such as exendin-4 (Ex-4). To study the consequences of sustained exposure to Ex-4, we generated metallothionein promoter–exendin-4 (MT-Exendin) mice that continuously express a proexendin-4 transgene in multiple murine tissues. We now report that MT-Exendin mice develop extensive tissue lymphocytic infiltration with increased numbers of CD4+ and CD8a+ cells in the liver and/or kidney and increased numbers of B220+ cells present in the pancreas and liver. MT-Exendin mice generate antibodies directed against Ex-4, exendin NH2-terminal peptide (ENTP), and proexendin-4 as well as antibodies that cross-react with native GLP-1. Furthermore, lymphocytes isolated from MT-Exendin mice proliferate in response to proexendin-4 but not after exposure to Ex-4 or ENTP. These findings demonstrate that expression of a proexendin-4 transgene may be associated with activation of humoral and cellular immune responses in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“0/5 (0) 0/12 (0) 1/18 (6) MT-Ex L19 2/11 (18) 5/22 (23)† 9/32 (28) MT-Ex L18 0/7 (0) 3/16 (19) 6/26 (23) Females B6 0/6 (0) 1/12 (8) 2/18 (11) Tg.”
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“Despite the efficacy of continuous GLP-1 administration for the treatment of type 2 diabetic patients (3), the clinical potential of the native peptide is hampered by its very short plasma half-life, due to rapid inactivation of GLP-1 by the ubiquitous protease dipeptidyl peptidase-4 (DPP-4) (4) and by renal clearance.”
BackgroundKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Cited by
Sherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., & Herold, K. C. (2007) · Endocrinology · doi:10.1210/en.2007-0358 · Cited by 169
“We considered whether exendin-4 could modify the islets themselves, thereby affecting their antigenicity, or in some way affect the autoimmune response as has been recently suggested (26).”
BackgroundGupta, N. A., Kolachala, V. L., Jiang, R., Abramowsky, C., Romero, R., Fifadara, N., Anania, F., Knechtle, S., & Kirk, A. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.07.015 · Cited by 60
Samson, S. L., Gonzalez, E. V., Yechoor, V., Bajaj, M., Oka, K., & Chan, L. (2008) · Molecular Therapy · doi:10.1038/mt.2008.198 · Cited by 54
Exendin‐4 Therapy in NOD Mice with New‐Onset Diabetes Increases Regulatory T Cell Frequency
Xue, S., Wasserfall, C. H., Parker, M., Brusko, T. M., McGrail, S., McGrail, K., Moore, M., Campbell‐Thompson, M., Schatz, D. A., Atkinson, M. A., et al. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1447.049 · Cited by 51
Metadata
- Authors
- Baggio, L. L., Holland, D., Wither, J., & Drucker, D. J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2006-06-01
- Volume
- 55
- Issue
- 6
- Pages
- 1562-1570
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2119960290
- Cited by
- 21
- References
- 4
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lymphocytic Infiltration and Immune Activation in Metallothionein Promoter–Exendin-4 (MT-Exendin) Transgenic Mice. https://app.cochat.ai/papers/10.2337/db05-1502
- The paper
- Baggio, L. L., Holland, D., Wither, J., & Drucker, D. J. (2006). Lymphocytic Infiltration and Immune Activation in Metallothionein Promoter–Exendin-4 (MT-Exendin) Transgenic Mice. Diabetes. https://doi.org/10.2337/db05-1502
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.